Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell transplantation in ankylosing spondylitis
ChiCTR-TRC-11001417Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2011
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mesenchymal stem cells, 5-aminosalicylic acid + sulphasalazine and indomethacin in ankylosing spondylitis (AS) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Pain degree of peripheral joints with visual analog scale, CD4+ T cell, CD8+ T cell, NK cell, Th17, Treg cell counts and 8 more. Started Sep 2011; status: recruiting.
02
Drugs
mesenchymal stem cells5-aminosalicylic acid + sulphasalazineindomethacin
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR-TRC-11001417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001417.